HCC phenotype
Evidence from:
primary |
all sources
No related entities found.
Mentioned in (13)
Papers in which this entity is mentioned.
- Integrated in vivo combinatorial functional genomics and spatial transcriptomics of tumours to decode genotype-to-phenotype relationships. (2026)
- Towards understandings of serine/arginine-rich splicing factors. (2023)
- At the dawn: cell-free DNA fragmentomics and gene regulation. (2022)
- Epigenetic analysis of cell-free DNA by fragmentomic profiling. (2022)
- Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. (2021)
- Application of third-generation sequencing in cancer research. (2021)
- Systematic evaluation of differential splicing tools for RNA-seq studies. (2020)
- Emerging Roles of SRSF3 as a Therapeutic Target for Cancer. (2020)
- The repertoire of mutational signatures in human cancer. (2020)
- The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer. (2018)
- MBASED: allele-specific expression detection in cancer tissues and cell lines. (2014)
- CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. (2014)
- Absolute quantification of somatic DNA alterations in human cancer. (2012)
Merged raw entities (4)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| hcc | phenotype | 21 | 61 |
| hcc cells | phenotype | 2 | 3 |
| human hepatocellular carcinoma | phenotype | 1 | 1 |
| hcc outcome | phenotype | — | — |